Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines

scientific article published in April 2002

Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1001/ARCHINTE.162.8.921
P698PubMed publication ID11966344

P50authorSue GoldieQ7634103
Milton WeinsteinQ30223679
Elena LosinaQ55523364
A. David PaltielQ58704489
Kenneth A. FreedbergQ87347438
George SeageQ90086356
April D. KimmelQ90776420
P2093author name stringHong Zhang
Donald E Craven
Jonathan E Kaplan
Calvin J Cohen
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectpneumoniaQ12192
Pneumocystis cariniiQ2099992
P304page(s)921-928
P577publication date2002-04-01
P1433published inJAMA Internal MedicineQ177428
P1476titleProphylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines
P478volume162

Reverse relations

cites work (P2860)
Q33636804A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing
Q37023469A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy
Q37259653Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives
Q59353398Autoimmune blistering disorders in the setting of human immunodeficiency virus infection
Q36628019Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy
Q34020879Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine.
Q36628399Cost-effectiveness of HIV testing and treatment in the United States
Q35692811Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.
Q44509935Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection
Q35575721Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India
Q24245223Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole
Q24245408Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole
Q47968071Dapsone-Induced Acute Pancreatitis
Q35967212Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database
Q38898943Modeling the cost-effectiveness of health programs: HIV testing and early treatment in the USA.
Q44255331Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis.
Q36948496Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care
Q34423942The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa
Q31082790The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis
Q47431983Utilities Derived from Visual Analog Scale Scores in Patients with HIV/AIDS
Q44261958Variations in self-rated health among patients with HIV infection

Search more.